secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-01-16T23:59:59+00:00
Accession:  0000950170-25-006191
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara receives FDA Complete Response Letter for EBVALLO BLA due to third-party manufacturing issues
--------------------------------------------------------------------------------

- FDA CRL solely related to third-party manufacturer inspection findings; no clinical efficacy/safety issues, no new trials requested.
- Atara expects resubmission within 6 months after GMP compliance resolved; potential approval within 6 months of resubmission.
- Preliminary cash and investments ~$43M as of Dec 31, 2024; non-binding term sheet with Redmile for up to $15M equity line.
- Atara exploring strategic alternatives; may suspend CAR-T activities if no funding by Q1 2025; committed to preserving EBVALLO value.
- Atara remains eligible for $60M milestone from Pierre Fabre upon FDA approval and double-digit royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025006191/0000950170-25-006191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025006191/atra-20250116.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-006191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer